Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab - Wikidata - awgldk - TriplyDB

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

http://www.wikidata.org/entity/Q35076449

about

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.

P2860

Q26801292-DE76B409-F8A5-4077-A54C-EC918C04475D Q38770131-43078C8B-5F09-4122-A100-9D1BCD6DA929

P2860

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

http://www.wikidata.org/entity/Q35076449

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@ast

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@en

type

label

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@ast

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@en

prefLabel

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@ast

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@en

P1433

Q35076449-9BBB8990-05F1-4AA3-B85E-7E563FAD6222

P1476

Q35076449-02A8B235-9787-4DDD-A523-3F0F7E4825EF

P2093

Q35076449-25EC9770-15E6-4ADD-ACCB-58F0438C1C3F

P2860

Q35076449-1612C413-5027-4B94-A712-53D636E95819

Q35076449-1AEBE218-7C26-443B-A112-76B51FFFED54

Q35076449-25E7863A-D389-4C84-83C8-EE1B41326E41

Q35076449-3FA8792E-CB88-4E22-A483-100F81B070FF

Q35076449-429C9804-8A61-4C69-A7CC-872F69C44EE6

Q35076449-445DD979-7649-46C0-BFE0-4B8F3B764E9F

Q35076449-45E413CB-92F5-41AF-B8EA-CA8BC7525C3D

Q35076449-46AB4D5A-037F-43B8-9240-F33AB0595F0F

Q35076449-47FBCAB0-6A63-436F-924B-0C5EB853DF95

Q35076449-489DEDC7-2E35-478D-902F-01D4A0722673

P304

Q35076449-4BAB0647-60A0-473E-8C81-B25E3BC7D2E2

P31

Q35076449-40F8D8CC-E664-474F-893A-BD4C8BFC5C38

P356

Q35076449-E515A224-3210-4B35-8667-A606E75EF17E

P478

Q35076449-95207499-070C-4F05-BEDD-0329701DE4F8

P50

Q35076449-0632857F-9C49-48F1-B0B3-97E72055EEA6

P577

Q35076449-33BE1DEE-C5ED-4A9B-8892-61369B4DE36D

P5875

Q35076449-DF5CC6C9-64F3-4DB9-B52E-8FEE3F7636F2

P698

Q35076449-EB83B88B-05A5-4969-AAAC-120680EE56DD

P921

Q35076449-6467BA2D-08AE-4BE0-B136-CEDDD1DA3A93

P932

Q35076449-CEF20B31-2D00-4E85-9ED5-27F64CC31DA2

P356

P1433

Pharmacogenomics and Personalized Medicine

P1476

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

@en

P2093

Lukáš Smolej

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Clinical staging of chronic lymphocytic leukemia.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PGPM.S55501

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272514227

http://www.w3.org/2001/XMLSchema#string

P698

25691812

http://www.w3.org/2001/XMLSchema#string

P921

P932

4325625

http://www.w3.org/2001/XMLSchema#string